Atlas Trials

Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)

Clinical trial NCT05131711 · UNKNOWN

Trial details

NCT number
NCT05131711
Sponsor
Beijing Tiantan Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2021-11-16
Primary completion
2022-11-16
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.